Nadler CV 8/94

CURRICULUM VITAE

Name: Lee M. Nadler

Address: 36 Cross Hill Road, Newton, MA 02459

Date of Birth: May 22, 1947

Place of Birth: Bronx, New York, NY

Education:

1969 B.A. Queens College of the City University of New York, NY

1973 M.D. Harvard Medical School, Boston, MA

Postdoctoral Training:

Internship and Residencies:

1973-1974 Intern, Columbia-Presbyterian Hospital, New York, NY

1974-1975 Resident, Columbia-Presbyterian Hospital, New York, NY

Fellowships:

1975-1977 Clinical Associate, Immunology Branch of the National Cancer Institute, Bethesda, MD

1977-1979 Clinical Fellow in Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

1977-1979 Clinical Fellow in Medicine, Harvard Medical School, Boston, MA

Academic Appointments:

1977-1979 Clinical Fellow in Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

1979-1981 Instructor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

1981-1984 Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

1984-1992 Associate Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

1992- Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

2002- Virginia and D.K. Ludwig Professor of Medicine, Harvard Medical School, Boston, MA

2002- Pan Mass Challenge Senior Investigator, Dana-Farber Cancer Institute, Boston, MA

Hospital Appointments:

1977-1979 Assistant in Medicine, Peter Bent Brigham Hospital, Boston, MA

1979-1982 Junior Associate in Medicine, Peter Bent Brigham Hospital, Boston, MA

1979-1981 Clinical Associate in Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

1981-1984 Assistant Physician in Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

1982-1992 Associate Physician, Brigham and Women's Hospital, Boston, MA

1984-1992 Associate Physician in Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

1992- Senior Physician, Brigham and Women's Hospital, Boston, MA

1992- Physician, Dana-Farber Cancer Institute, Boston, MA

Leadership and Committee Assignments:

1993- Adult Scientific Review Committee, Dana-Farber Cancer Institute, Boston, MA

1993-1996 Chief, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA

1995- Leader, Clinical Immunology Program, Cancer Center Core Grant, Dana-Farber Cancer Institute, Boston, MA

1995-1996 Leader, Quality Improvement, Dana-Farber Cancer Institute, Boston, MA

1995- Member, Executive Committee for Research, Dana-Farber Cancer Institute, Boston, MA

1996-1998 Leader, Hematologic Malignancies Program, Dana-Farber/ Partners CancerCare, Boston, MA

1996-1997 Chief, Experimental Oncology, Dana-Farber Cancer Institute, Boston, MA

1996-2001 Member, Medical Coordinating Committee, Dana-Farber/Partners CancerCare, Boston, MA

1996- Member, Medical Staff Executive Committee, Dana-Farber Cancer Institute, Boston, MA

1996- Member, Executive Management Group, Dana-Farber Cancer Institute, Boston, MA

1997-2001 Chief, Division of Medical Oncology, Brigham and Women's Hospital, Boston, MA

1997-2001 Chair, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA

2001- Senior Vice President, Experimental Medicine, Dana-Farber Cancer Institute, Boston, MA

2001- Member, Clinical Research Coordinating Committee, Dana-Farber/Partners CancerCare, Boston, MA

2003- Director, Center for Clinical and Translational Research, Dana-Farber Cancer Institute, Boston, MA

Honors and Awards:

1989 The American Society for Clinical Investigation

1998 AACR Richard and Hinda Rosenthal Foundation Award

2000 Association of American Physicians

2002 AACR Joseph H. Burchenal Clinical Research Award

2002 Virginia and D.K. Ludwig Professor of Medicine, Harvard Medical School

2002 Pan Mass Challenge Senior Investigator, Dana-Farber Cancer Institute

Major Research Interests:

1. Identification and Characterization of Costimulatory Molecules on Antigen Presenting Cells and their T Cell Counter-Receptors

2. Novel Translational Strategies for Liquid and Solid Tumors

3. Induction of Anti-Tumor Specific Immunity

4. Induction of T-Cell Anergy and Clonal Deletion to Expand the Allogeneic Donor Pool

Bibliography

Original Reports:

1. Villalba-Pimental L, Epstein LM, Sellers EM, Nadler LM, Foster JR, Bennion LJ, Bough EW and Koch-Weser J. Survival after massive procainamide ingestion. Am J Cardio 1973; 32:727-730.

2. Nadler LM and Hodes RJ. Regulatory mechanisms in cell-mediated immune responses. II. Comparison of culture-induced and alloantigen-induced suppressor cells in MLR and CML. J Immunol 1977; 118:1889-1895.

3. Hodes RJ, Nadler LM and Hathcock KS. Regulatory mechanisms in cell-mediated immune responses. III. Antigen-specific and non-specific suppressor activities generated during MLC. J Immunol 1977; 119:961-967.

4. Reinherz EL, Nadler LM, Sallan SE and Schlossman SF. T cell subset characterization of human T-CLL. Blood 1979; 53:1066-75.

5. Reinherz EL, Nadler LM, Sallan SE and Schlossman SF. Subset derivation of T cell acute lymphoblastic leukemia in man. J Clin Invest 1979; 64:392-397.

6. Pinkus GS, Hargreaves HK, McLeod JA, Nadler LM, Rosenthal DS and Said JW. Alpha-napththyl acetate esterase activity - a cytochemical marker for T lymphocytes. Correlation with immunologic studies of normal tissues, lymphocytic leukemias, non-Hodgkin's lymphomas, Hodgkin's disease, and other lymphoproliferative disorders. Am J Path 1980; 97:17-40.

7. Nadler LM, Reinherz EL and Schlossman SF. The T lymphoblastic malignancies. Cancer Chemother and Pharmacol 1980; 4:11-15.

8. Nadler LM, Stashenko P, Hardy R and Schlossman SF. A monoclonal antibody defining a lymphoma associated antigen in man. J Immunol 1980; 125:570-577.

9. Nadler LM, Reinherz EL, Weinstein HJ, D'Orsi CJ and Schlossman SF. Heterogeneity of T cell lymphoblastic malignancies. Blood 1980; 55: 806-810.

10. Stashenko P, Nadler LM, Hardy R and Schlossman SF. Characterization of a new B lymphocyte specific antigen in man. J Immunol 1980;125:1678-1685.

11. Nadler LM, Stashenko P, Hardy R, Kaplan WB, Button LN, Kufe DW, Antman KH and Schlossman SF. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40:3147-3154.

12. Nadler LM, Stashenko P, Ritz J, Hardy R, Pesando JM and Schlossman SF. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981; 67:134-140.

13. Nadler LM, Stashenko P, Hardy R, Pesando JM, Yunis EJ and Schlossman SF. Monoclonal antibodies defining serologically distinct HLR-D/DR related Ia-like antigens in man. Human Immunol 1981; 1:77-90.

14. Nadler LM, Stashenko P, Hardy R, van Agthoven A, Terhorst C and Schlossman SF. Characterization of a human B cell specific antigen (B2) distinct from B1. J Immunol 1981; 126: 1941-1947.

15. Todd RF III, Nadler LM and Schlossman SF. Antigens on human monocytes identified by monoclonal antibodies. J Immunol 1981; 126: 1435-1442.

16. Pesando JM, Nadler LM, Lazarus H, Tomaselli KJ, Stashenko P, Ritz J, Levine H, Yunis EJ and Schlossman SF. Human cell lines express multiple populations of Ia-like molecules. Human Immunol 1981; 3: 67-76.

17. Boumsell L, Bernard A, Reinherz EL, Nadler LM, Ritz J, Coppin H, Richard Y, Dubertret L, Degos L, Lemerle J, Flandrin G, Dausset J and Schlossman SF. Surface antigens on malignant Sezary and T-CLL cells correspond to those of mature T cells. Blood 1981; 57: 526-530.

18. Posner MR, Reinherz EL, Breard J, Nadler LM, Rosenthal DS and Schlossman SF. Lymphoid subpopulations of peripheral blood and spleen in untreated Hodgkin's disease. Cancer 1981; 48: 1170-1176.

19. Todd RF III, Griffin JD, Ritz J, Nadler LM, Lazarus H, Abrams T and Schlossman SF. Expression of monocyte-macrophage differentiation antigens on HL6O promyelocytes undergoing differentiation induced by leukocyte-conditioned medium on phorbol diester. Leuk Res 1981; 5: 491-495.

20. Nadler LM, Stashenko P, Hardy R, Tomaselli KJ, Yunis EJ, Schlossman SF and Pesando JM. A monoclonal antibody identifying a new Ia-like polymorphic system linked to HLA-D/DR region. Nature 1981; 290: 591-593.

21. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB and Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-1337.

22. Stashenko P, Nadler LM, Hardy R and Schlossman SF. Expression of cell surface markers following human B lymphocyte activation. Proc Natl Acad Sci, USA 1981; 78: 6: 3848-3852.

23. Bernard A, Boumsell L, Reinherz EL, Nadler LM, Ritz J, Coppin H, Richard Y, Valensi F, Dausset J, Flandrin G, Lemerle J and Schlossman SF. Malignant T cells from acute lymphoblastic leukemia and from malignant lymphomas exhibit different patterns of surface antigens. Blood 1981; 57: 1105-1110.

24. Bhan AK, Nadler LM, Stashenko P and Schlossman SF. Stages of B cell differentiation in human lymphoid tissues. J Exp Med 1981; 154: 737-749.

25. Ritz J, Nadler LM, Bhan AK, Notis-McConarty J, Hardy R and Schlossman SF. Expression of the common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B cell and T cell lineage. Blood 1981; 58: 648-652.

26. Griffin JD, Ritz J, Nadler LM and Schlossman SF. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest 1981; 68: 932-941.

27. Hercend T, Nadler LM, Pesando JM, Schlossman SF and Reinherz EL. Expression of a 26,000 dalton glycoprotein on activated human T cells. Cellular Immunol 1981; 64: 192-209.

28. Posner MR, Said J, Pinkus GS, Nadler LM, Hardy R and Skarin AT. T cell lymphoblastic lymphoma with subsequent acute non-lymphocytic leukemia. Cancer 1982; 50: 118-124.

29. Morimoto C, Reinherz EL, Nadler LM, Distaso JA, Steinberg AD and Schlossman SF. Comparison of T and B cell markers in patients with Sjogren's syndrome and systemic lupus erythrematosus. Clin Immunol Immunopathol 1982; 22:270-278.

30. McAdam KPWJ, Li J, Knowks J, Foss NT, Dinarello CA, Rosenwasser LJ, Selinger MJ, Kaplan MM, Goodman R, Herbert PN, Bausserman LL and Nadler LM. The biology of SAA: Identification of the inducer, in vitro synthesis and heterogeneity demonstrated with monoclonal antibodies. Ann of New York Acad of Sci 1982; 389:126-136.

31. Nadler LM, Ritz J, Bates M, Park EK, Anderson KC, Sallan SE and Schlossman SF. Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. J Clin Invest 1982; 70:433-442.

32. Thorley-Lawson DA, Schooley RT, Bhan AK and Nadler LM. Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-last 1) expressed on transformed lymphoblasts. Cell 1982; 30: 415-425.

33. Shaw S, DeMars R, Schlossman SF, Smith PL, Lampson LA and Nadler LM. Serologic identification of the human secondary B cell (SB) antigens: Correlations between function, genetics, and structure. J Exp Med 1982; 156: 731-743.

34. Hurley C, Shaw S, Nadler LM, Schlossman SF and Capra JD. The alpha and beta chains of SB and DR antigens are structurally distinct. J Exp Med 1982; 156: 1157-1162.

35. Fram R, Skarin AT, Rosenthal DS, Pinkus G and Nadler LM. Clinical and pathological features of patients with non-Hodgkin's lymphoma in leukemic phase: A retrospective analysis of 34 patients. Cancer 1983; 52: 1220-1228.

36. Kufe D, Nadler LM, Sargent L, Shapiro H, Colcher D and Schlom J. Cell surface binding properties of monoclonal antibodies reactive with human mammary carcinoma cells. Cancer Res 1983; 43: 851-857.

37. Griffin JD, Todd RF, Ritz J, Nadler LM, Canellos GP, Rosenthal D, Gallivan M, Beveridge RP, Weinstein H, Karp D and Schlossman SF. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood 1983; 61: 85-91.

38. Hokland P, Rosenthal P, Griffin JD, Nadler LM, Daley J, Hokland M, Schlossman SF and Ritz J. Purification and characterization of fetal hematopoietic cells which express the common acute lymphoblastic leukemia antigen (CALLA). J Exp Med 1983; 157: 114-129.

39. Anderson KC, Park E, Bates M, Leonard RCF, Schlossman SF and Nadler LM. Antigens on human plasma cells identified by monoclonal antibodies. J. Immunol 1983; 130: 1132-1138.

40. Oettgen HC, Bayard PJ, vanEwijk W, Nadler LM and Terhorst CP. Further biochemical studies of the human B cell differentiation antigens B1 and B2. Hybridoma 1983; 2: 17-28.

41. Rosenthal P, Rimm IJ, Umiel T, Griffin JD, Schlossman SF and Nadler LM. Characterization of fetal lymphoid tissue by monoclonal antibodies. J Immunol 1983; 131: 232-237.

42. Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF and Schlossman SF. B4, a human B cell associated antigen expressed on normal, mitogen activated, and malignant B lymphocytes. J Immunol 1983; 131: 244-250.

43. Iida K, Nadler LM and Nussenzweig V. The complement fragment C3d is a ligand for the human B lymphocyte membrane antigen B2. J Exp Med 1983; 158: 1021-1033.

44. Lipton JM, Nadler LM, Canellos GP, Kudisch M and Nathan DG. Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man. J Clin Invest 1983; 72: 694-706.

45. Anderson KC, Griffin JD, Bates MP, Slaughenhoupt B, Schlossman SF and Nadler LM. Isolation and characterization of human B lymphocyte enriched populations. I. Purification of B cells by immune rosette depletion. J Immunol Meth 1983; 61: 283-292.

46. Bast RC, DeFabritiis P, Lipton J, Gelber R, Mayer C, Nadler LM, Sallan S and Ritz J. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 1983; 45: 499-508.

47. Antman KH, Nadler LM, Mark ES, Montella DL, Kirkpatrick P and Halpern J. Primary Kaposi's Sarcoma of the lung in an immunocompetent 32 year old heterosexual white male. Cancer 1984; 56: 1696-1698.

48. Letvin NL, Aldrich WR, Thorley-Lawson D, Schlossman SF and Nadler LM. Surface antigen changes during B lymphocyte activation in primates. Cellular Immunology 1984; 84: 163-170.

49. Hokland P, Nadler LM, Griffin JD, Schlossman SF and Ritz J. Purification of the common acute lymphoblastic leukemia antigen (CALLA) positive cells from normal bone marrow. Blood 1984; 64: 662-666.

50. Anderson KC, Slaughenhoupt B, Bates MP, Pinkus G, O'Hara C, Schlossman SF and Nadler LM. Expression of human B cell associated antigens on leukemia and lymphomas: A model of human B cell differentiation. Blood 1984; 63:1424-1433.

51. Nadler LM, Korsmeyer SJ, Anderson KC, Boyd AW, Slaughenhoupt B, Park E, Jensen J, Coral F, Mayer RJ, Sallan SE, Ritz J and Schlossman SF. The B cell origin of non-T cell acute lymphoblastic leukemia: A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest 1984; 74: 332-340.

52. Linch DC, Nadler LM, Luther EA and Lipton LM. Discordant expression of human Ia-like antigens on hematopoietic progenitor cells. J Immunol 1984; 132: 2324-2329.

53. Nadler LM, Takvorian T, Botnick L, Bast RC, Finberg R, Hellman S, Canellos GP and Schlossman SF. Anti-B1 monoclonal antibody and complement treated autologous bone marrow transplantation for relapsed B cell non-Hodgkin's lymphoma. Lancet 1984; 427-430.

54. Anderson KC, Bates MP, Slaughenhoupt B, Schlossman SF and Nadler LM. A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells. J Immunol 1984; 132: 3172-3179.

55. Harris NL, Nadler LM and Bhan AK. Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies: Follicular and diffuse lymphomas of small cleaved cell type are related but distinct entities. Am J Path 1984; 117: 262-272.

56. Hurley CK, Giles RC, Nunez G, DeMars R, Nadler LM, Winchester R, Stastny P and Capra JD. Molecular localization of human class II MT2 and MT3 determinants. J Exp Med 1984; 162: 420-428.

57. Marti GE, Nadler LM, Chused TM, Tosato G, Blaese RM and Kindt TJ. Cellular distribution of Ia-like (DS/DC) antigen on normal and neoplastic lymphoid cells. Human Immunol 1985; 12: 23-35.

58. DeFabritiis P, Bregni M, Lipton J, Greenberger J, Nadler LM, Rothstein L, Korbling M, Ritz J and Bast RC. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosamide (4HC) in combination with monoclonal antibodies and complement. Blood 1985; 65: l064-1070.

59. Anderson KC, Boyd AW, Fisher D, Slaughenhoupt B, Groopman E, O'Hara CJ, Daley JF, Schlossman SF and Nadler LM. Isolation and functional analysis of human B cell populations: I. Characterization of the B1+B2+ and B1+B2- subset. J Immunol 1985; 134: 820-827.

60. Anderson KC, Boyd AW, Leslie D, Fisher DC, Schlossman SF and Nadler LM. Hairy cell leukemia: A tumor of pre-secretory B cells. Blood 1985; 65: 620-629.

61. Freedman AS, Boyd AW, Anderson KC, Fisher D, Pinkus G, Schlossman SF and Nadler LM. Immunologic heterogeneity of diffuse large cell lymphoma. Blood 1985; 65: 630-637.

62. Greenberger JS, Rothstein L, DeFabritiis P, Bregni M, Bast RC, Ritz J, Nadler LM, Lipton J and Sakakeeny MA. Effects of monoclonal antibody and complement treatment of human bone marrow on hematopoiesis in continuous bone marrow culture. Cancer Res 1985; 45: 758-767.

63. Freedman AS, Boyd AW, Anderson KC, Fisher DC, Schlossman SF and Nadler LM. B5, a new B cell activation antigen. J Immunol 1985; 134: 2228-2235.

64. Boyd AW, Freedman AS, Anderson KC, Fisher DC, Slaughenhoupt B, Schlossman SF and Nadler LM. Studies on in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional studies on the response to anti-Ig antibody. J Immunol 1985; 134: 1516-1523.

65. Bast RC, Jr. De Fabritiis P, Lipton J, Gelber R, Maver C, Nadler LM, Sallan S and Ritz J. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Research 1985; 45: 499-503.

66. Boyd AW, Fisher DC, Schlossman SF and Nadler LM. Structural and functional characterization of IL-2 receptors on activated human B cells. J Immunol 1985; 134: 2387-2392.

67. Thorley-Lawson DA, Nadler LM, Bhan A and Schooley RT. Blast-2 (EBVCS): An early cell surface marker of human B cell activation is superinduced by Epstein-Barr virus. J Immunol 1985; 134: 3007-3012.

68. Hokland P, Ritz J, Schlossman SF and Nadler LM. Orderly expression of B cell antigens during the in vitro differentiation of non-malignant human pre-B cell. J Immunol 1985; 135: 1746-1751.

69. Tedder TF, Boyd AW, Freedman AS, Nadler LM and Schlossman SF. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985; 135: 973-979.

70. Bregni M, De Fabrotoos P, Rasp V, Greenberger J, Lipton J, Nadler LM, Rothstein L, Ritz J and Bast RC Jr. Elimination of Cconogenic tumor cells from human bone marrow using a combination of monoclonal antibody: Ricin a chain conjugate. Cancer Research 1986; 46: 1208-1213.

71. Boyd AW, Freedman AS, Horowitz JC, Anderson KC, Fisher DC, Rosen KJ, Schlossman SF and Nadler LM. Studies of the in vitro activation and differentiation of human B lymphocytes. II. Optimization of activation by anti-immunoglobulin antibody bound to beads: analysis of role of autocrine effects on B cell proliferation and of T cell help in B cell differentiation. Cell Immunol 1986; 99: 228-240.

72. Anderson KC, Roach JA, Daley JF, Schlossman SF and Nadler LM. Dual fluorochrome analysis of human B lymphocytes: Phenotypic examination of resting, anti-immunoglobulin stimulated, and in vivo activated B cells. J Immunol 1986; 136: 3612-3618.

73. Dorken B, Moldenhauer G, Pezzuto A, Schwartz R, Feller A, Keisel S and Nadler LM. HD-39 (B3), a B lineage restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 1986; 136: 4470-4479.

74. Tedder TF, Boyd AW, Nadler LM and Schlossman SF. Antibodies reactive with the B1 molecule inhibit cell cycle progression of activated human B cells. European J Immunol l986; 88l-887.

75. Natal P, Bigott A, Cavalieri R, Nicotra MR, Tecce R, Manfredi D, Chen Y, Nadler LM and Ferrone S. Gene products of the HLA-D region in normal and malignant tissues of nonlymphoid origin. Human Immunol 1986; 15: 220-233.

76. Freedman AS, Boyd AW, Berrebi A, Horowitz JC, Rosen KJ, Slaughenhoupt B, Levy D, Daley J, Levine H and Nadler LM. Expression of B cell activation antigens on normal and malignant B cells. Leukemia 1987; 1: 9-15.

77. Anderson KC, Ritz J, Takvorian T, Coral F, Daley J, Gorgone BA, Freedman AS, Schlossman SF and Nadler LM. Hematologic engraftment and immune reconstitution post-transplantation with anti-B1 purged autologous bone marrow. Blood l987; 69: 597-604.

78. Boyd AW, Tedder TF, Griffin JD, Freedman AS, Fisher DC and Nadler LM. Pre-exposure of resting B cells to gamma-interferon enhances then proliferative response to subsequent activation signals. Cellular Immunol 1987; 106: 355-365.

79. Freedman AS, Boyd AW, Bieber FR, Daley J, Rosen K, Horowitz JC, Levy DN and Nadler LM. Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood l987; 70: 418-427.

80. Letvin NL, Zalutsky MR, Lambert JM, Chalifoux LV, Nadler LM, Schlossman SF and Atkins HL. Use of Radiolabeled monoclonal anti-Bl antibody for B lymphocyte imaging in rhesus monkeys. Int J Radiat Appl Instrum l987; 14: 99-105.

81. Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch P, Tarbell N, Coral F, Daley H, Yeap B, Schlossman S and Nadler LM. Prolonged disease-free survival in patients with poor prognosis non-Hodgkins lymphoma following autologous bone marrow transplantation. N Engl J Med l987; 3l6: 1499-1505.

82. Nadler LM. The challenge of bone marrow purging. Bone Marrow Transplantation 1987; 2: 5-13.

83. Freedman AS, Freeman G, Horowitz JC, Daley J and Nadler LM. B7, a B cell restricted antigen which identifies pre-activated B cells. J Immunol 1987; 137: 3260-3267.

84. Freedman AS, Freeman G, Whitman J, Segil J, Daley J and Nadler LM. Pre-exposure of human B cells to recombinant interleukin 1 enhances subsequent proliferation. J Immunol 1988; 141: 3398-3404.

85. Freedman AS, Freeman G, Whitman J, Segil J, Daley J and Nadler LM. Studies of in vitro activated CD5+ B cells. Blood 1989; 73: 202-208.

86. Freeman GJ, Freedman AS, Rabinowe SN, Segil JM, Horowitz J, Rosen K, Whitman JF and Nadler LM. Interleukin-6 gene expression in normal and neoplastic B cells. J Clin Invest 1989; 83: 1512-1518.

87. Freedman AS, Freeman G, Whitman J, Segil J, Daley J, Levine H and Nadler LM. Expression and regulation of CD5 on in vitro activated human B cells. Eur J Immunol 1989; 19: 849-855.

88. Schriever F, Freedman AS, Freeman G, Messner E, Lee G, Daley J and Nadler LM. Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med 1989; 169: 2043-2058.

89. Bashir R, Freedman A, Harris N, Bain K, Nadler LM and Hochberg F. Immunophenotypic profile of CNS lymphoma: a review of eighteen cases. J Neurooncol 1989; 7: 249-254.

90. Bosserman LD, Murray C, Takvorian T, Anderson KC, Freedman AS, Fitzsimmons J, Coral F, Nadler LM, Schlossman SF and Ritz J. Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bone Marrow Transpl 1989; 4: 239-245.

91. Pedrazzini A, Freedman AS, Andersen J, Heflin L, Anderson K, Canellos GP, Whitman J, Coral F, Ritz J and Nadler LM. Anti-B cell MoAb purged autologous bone marrow transplantation for B cell non-Hodgkin's lymphoma: Phenotypic reconstitution and B cell function. Blood 1989; 74: 2203-2211.

92. Freeman GF, Freedman AS, Segil J, Lee G, Whitman JF and Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989; 143: 2714-2722.

93. Spector NL, Freedman AS, Freeman G, Segil J, Whiteman JF, Welch WJ and Nadler LM. Activation primes human B lymphocytes to respond to heat shock. J Exp Med 1989; 170: 1763-1767.

94. Anderson KC, Barut BA, Ritz J, Freedman AS and Nadler LM. Autologous bone marrow transplantation therapy for multiple myeloma. Eur J Hematol 1989; 43: 157-163.

95. Roy DC, Trantravhi R, Murray C, Dear K, Gorgone B, Anderson KC, Freedman AS, Nadler LM and Ritz J. Natural history of mixed chimerism following bone marrow transplantation with CD6 depleted allogenic transplantation. Blood 1990; 75: 296-304.

96. Dadmarz R, Rabinowe S, Cannistra S, Anderson JD, Freedman AS and Nadler LM. Association between clonogeneic cell growth and clinical risk group In B-cell chronic lymphocytic leukemia. Blood 1990; 76: 142-149.

97. Freedman AS, Ritz J, Takvorian T, Anderson KC, Mauch P, Rabinowe SN, Blake K, Yeap B, Coral F, Heflin L and Nadler LM. Autologous bone marrow transplantation in B cell non-Hodgkin's lymphoma: Very low treatment related mortality in 100 patients in sensitive relapse. J Clin Onc 1990; 8: 779-784.

98. Kaplan WD, Jochelson MS, Herman TS, Nadler LM, Stomper PC, Takvorian T, Andersen JW and Canellos GP. Gallium-67 Imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large cell lymphoma. J Clin Oncol 1990; 8: 1966-1970.

99. Freedman AS, Munro JM, Rice GE, Bevilacqua MP, Morimoto C, McIntyre BW, Rhynhart K, Pober JS and Nadler LM. Human B cell localization to germinal centers is mediated through VLA-4 and the adhesion molecule INCAM-110. Science 1990; 249: 1030-1033.

100. Valle A, Garrone P, Yessel H, Bonnefoy J-Y, Freedman AS, Freeman G, Nadler LM and Banchereau J. MAB 104, a new monoclonal antibody, recognizes the B7 antigen which is expressed on activated B cells and HTVL-1 transformed T cells. Immunology 1990; 69: 531-535.

101. Anderson KC, Soiffer R, DeLage R, Takvorian T, Freedman AS, Rabinowe SL, Nadler LM, Dear K, Heflin L, Mauch P and Ritz J. T cell depleted bone marrow transplantation therapy: Analysis of immune deficiency and late complications. Blood 1990; 76: 235-244.

102. Ayash LJ, Hunt M, Antman K, Nadler LM, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T and Eder JP. Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol 1990; 8: 1699-1706.

103. Buckwald D, Freedman AS, Ablashi DV, Sullivan JL, Caligiuri MA, Weinberg DS, Hall CG, Ashley RL, Saxinger C, Balachandran N, Ritz J, Nadler LM and Komaroff AL. A chronic "postinfectious" fatigue syndrome associated with benign lymphoproliferation, B-cell proliferation, and active replication of human herpevirus-6. J Clin Immunol 1990; 10: 335-344.

104. Jochelson M, Tarbell N, Freedman AS, Rabinowe SN, Takvorian T, Soiffer R, Ritz J and Nadler LM. Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transpl 1990; 6: 329-331.

105. Soiffer RJ, Mauch P, Tarbell NJ, Anderson KC, Freedman AS, Rabinowe SN, Takvorian T, Murray CI, Coral F, Bosserman L, Dear K, Nadler LM and Ritz J. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transpl 1991; 23-33.

106. Anderson KC, Barut BA, Ritz J, Freedman AS, Takvorian T, Rabinowe SN, Soiffer R, Coral F, Heflin L, Mauch P and Nadler LM. Monoclonal antibody purged autologous bone marrow transplantation for multiple myeloma. Blood 1991; 77: 712-720.

107. Lew MA, Kehoe K, Ritz J, Antman KH, Nadler LM, Takvorian T, Mayer R, Kalish L and Finberg R. Prophylaxis of bacterial infections with Ciprofloxin in patients undergoing bone marrow transplantation. Transplantation 1991; 51: 630-635.

108. Schriever F, Freeman GJ and Nadler LM. Follicular dendritic cells contain a unique gene repertoire demonstrated by single-cell polymerase chain reaction. Blood 1991; 77: 787-791.

109. Freedman AS, Ritz J, Neuberg D, Anderson KC, Rabinowe SN, Mauch P, Takvorian T, Soiffer R, Blake K, Yeap B, Coral F and Nadler LM. Autologous Bone Marrow Transplantation in 69 patients with a history of low grade B cell non-Hodgkin's lymphoma. Blood 1991; 77: 2524-2529.

110. Rabinowe SN, Soiffer RJ, Tarbell NJ, Freedman AS, Seifter J, Blake KW, Neuberg D, Gribben JG, Anderson KC, Takvorian T, Ritz J and Nadler LM. Hemolytic-uremic syndrome following bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 1837-1844.

111. Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, Onetto N, Gillis S, Oette D, Gold M, Buckner CD, Hansen JA, Ritz J, Applebaum FR, Armitage JO and Nadler LM. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773-1778.

112. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C and Nadler LM. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci, USA 1991; 88: 6575-6579.

113. Soiffer RJ, Dear K, Rabinowe SN, Anderson KC, Freedman AS, Murray C, Tarbell NJ, Mauch P, Nadler LM and Ritz J. Hepatic dysfunction following T cell depleted allogeneic bone marrow transplantation. Transplantation 1991; 6: 1014-1019.

114. Freeman GJ, Gray GS, Gimmi CD, Lombard D, Zhou LJ, White M, Fingeroth JD, Gribben JG and Nadler LM. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 1991; 174: 625-632.

115. Freedman AS, Freeman GJ, Rhynhart K, Nadler LM. Selective induction of B7/BB1 on interferon-g stimulated monocytes: A potential mechanism for amplification of T cell activation through the CD28 pathway. Cell. Immunol 1991; 137: 429-437.

116. Gribben JG, Freedman AS, Woo S, Blake K, Shu R, Freeman G, Longtime J, Pinkus G and Nadler LM. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have bone marrow infiltration at evaluation and following treatment. Blood 1991; 78: 3275-3280.

117. Lambert JM, Goldmacher VS, Collinson AR, Nadler LM and Blaettler WA. An immunotoxin prepared with blocked ricin: A natural plant toxin adapted for therapeutic use. Cancer Res 1991; 51: 6236-6242.

118. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake K, Woo SD, Grossbard ML, Coral F, Freeman GJ, Ritz J and Nadler LM. Immunologic purging of polymerase chain reaction detectable lymphoma cells results in increased disease-free survival following autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma. N Engl J Med 1991; 325: 1526-1533.

119. Freeman GJ, Disteche CM, Gribben JG, DA, Freedman AS and Nadler LM. The gene for B7, a costimulatory signal of T cell activation, maps to chromosomal region 3q13.3-q21. Blood 1992; 79: 489-494.

120. Freedman AS, Munro MJ, Morimoto C, McIntyre BW, Rhynhart K, Lee N and Nadler LM. Follicular NHL cell adhesion to normal germinal centers and neoplastic follicles involves very late antigen-4 and vascular cell adhesion molecule-1. Blood 1992; 79: 206-212.

121. Reiser H, Freeman GJ, Razi-Wolf Z, Gimmi C, Benacerraf B and Nadler LM. The murine B7 antigen proves an efficient costimulatory signal for the activation of murine T lymphocytes via the TCR/CD3 complex. Proc Natl Acad Sci, USA 1992; 89: 271-275.

122. Spector NL, Samson W, Ryan C, Gribben JG, Urba W, Welch WJ and Nadler LM. Growth arrest of human B lymphocytes is accompanied by induction of the low molecular weight mammalian heat shock protein (Hsp28). J Immunol 1992; 148: 1668-1673.

123. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blattler WA, Taylor JA and Nadler LM. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion. Blood 1992; 79: 576-585.

124. Vandenberghe P, Freeman GJ, Nadler LM, Fletcher MC, Kamoun M, Turka L, Ledbetter JA, Thompson CB and June CH. Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. J Exp Med 1992; 175: 951-960.

125. Robertson MJ, Soiffer R, Griffin JD, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ, Murray C, Dear K, Nadler LM and Ritz J. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 1992; 79: 2229-2236.

126. Soiffer RJ, Anderson KC, Takvorian T, Freedman AS, Rabinowe SN, Coral F, Murray C, Freeman A, Dear K, Caligiuri MA, Roy DC, Rudders R, Miller K, Fugaren T, Tarbell NJ, Mauch P, Nadler LM and Ritz J. Prevention of graft-versus-host disease by selective depletion of CD 6 positive T lymphocytes from donor bone marrow. J Clin Oncol 1992; 10: 1191-1200.

127. Razi-Wolf Z, Freeman GJ, Galvin F, Benacerraf B, Nadler LM and Reiser H. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc Natl Acad Sci, USA 1992; 89: 4210-4214.

128. Freedman AS, Munro JM, Rhynhart K, Schow P, Daley J, Lee N, Svahn J, Eliseo L and Nadler LM. Follicular dendritic cells inhibit human B lymphocyte proliferation. Blood 1992; 80: 1284-1288.

129. Grossbard ML, Lambert JM, Goldmacher VS, Blattler WA and Nadler LM. Correlation between in vivo toxicity and pre-clinical in vitro parameters for the immunotoxin anti-B4 blocked ricin. Cancer Res 1992; 52: 4200-4207.

130. Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler LM and Glimcher LH. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992; 360: 266-268.

131. Gribben JG, Saporito L, Barber M, Blake K, Edwards RM, Griffin JD, Freedman AS and Nadler LM. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood 1992; 80: 1083-1089.

132. Freeman GJ, Lombard DB, Gimmi CD, Brod SA, Lee K, Laning JC, Hafler DA, Dorf ME, Gray GS, Reiser H, June CH, Thompson CB and Nadler LM. CTLA-4 and CD28 messenger RNA are coexpressed in most T cells following activation: Expression of CTLA-4 and CD28 messenger RNA does not correlate with the pattern of lymphokine production. J Immunol 1992; 149: 3795-3801.

133. LaSalle JM, Tolentino PJ, Freeman GJ, Nadler LM and Hafler DA. Early signalling defects in human T cells anergized by T cell presentation of autoantigen. J Exp Med 1992; 176: 177-186.

134. Galvin F, Freeman GJ, Razi-Wolf, Z, Hall Jr. W, Benacerraf B, Nadler LM and Reiser H. The murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. J Immunol 1992; 149: 3802-3808.

135. Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Blake KW, Woo SD, Saporito L, Coral F, Spector, Rabinowe SN, Ritz J and Nadler LM. Detection by PCR of residual cells with the bcl-2 translocation after autologous bone marrow transplantation for B-cell lymphoma is associated with poor prognosis. Blood 1993; 81: 3449-3457.

136.